<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epidemiological data show that <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is the second most frequent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>The involvement of "minor impact genes" such as XME and DNA-repair genes in the etiology of <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> has been postulated by other authors </plain></SENT>
<SENT sid="2" pm="."><plain>We focused on analyzing polymorphisms in DNA-repair genes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We considered the following genes involved in DNA-repair pathways: base excision repair (OGG1 Ser326Cys, XRCC1 Trp194Arg and Arg399Gln); nucleotide excision repair [<z:e sem="disease" ids="C0268135" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">XPA</z:e> (-4)G/A, XPC C/A (i11) and A33512C (Lys939Gln), <z:e sem="disease" ids="C0268138" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">XPD</z:e> Asp312Asn and A18911C (Lys751Gln), <z:e sem="disease" ids="C0268140" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="XP6">XPF</z:e> Arg415Gln, <z:e sem="disease" ids="C0268141" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="XP7">XPG</z:e> Asp1104His, ERCC1 C118T]; homologous recombination repair [NBS1 Glu185Gln, Rad51 135G/C, XRCC3 C18067 (Thr241Met)] </plain></SENT>
<SENT sid="4" pm="."><plain>The study group consisted of 133 patients diagnosed with <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, while the control group was composed of 100 age-matched non-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> volunteers </plain></SENT>
<SENT sid="5" pm="."><plain>Genotyping was performed by PCR and PCR-RFLP </plain></SENT>
<SENT sid="6" pm="."><plain>Fisher's exact test with a Bonferroni correction for multiple testing was used </plain></SENT>
<SENT sid="7" pm="."><plain>We found that: (i) XPC C/A (i11) heterozygous variant is associated with increased risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> [OR is 2.07 (95% CI 1.1391, 3.7782) P=0.038], (ii) <z:e sem="disease" ids="C0268138" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">XPD</z:e> A18911C (Lys751Gln) is associated with decreased risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> [OR=0.4497, (95% CI 0.2215, 0.9131) P=0.031] for an individual with at least one A allele at this locus </plain></SENT>
<SENT sid="8" pm="."><plain>(1) The XPC C/A (i11) genotype is associated with an increased risk of <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>(2) The NER pathway has been highlighted in our study, as a most important in modulation of individual susceptibility to sCRC </plain></SENT>
</text></document>